Astellas Shares DMD Community Newsletter

November 16, 2020

Astellas shares its community newsletter for the Duchenne community including an update on its Phase 1b Study: a study to assess the safety, tolerability and preliminary efficacy of ASP0367 (MA0211) in pediatric male participants with Duchenne muscular dystrophy (DMD). Click here to read the full newsletter.

Join Jett Foundation for a virtual presentation and live Q&A with Astellas on Wednesday, November 18, 2020 at 2:00PM ET. Register now!

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open